Annual report
4551.TEDINET S100QGWM
Period2022-01-01 → 2022-12-31
Filed2023-03-28
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 89
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥48.9bn | 2022-01-01 → 2022-12-31 | Standalone | Net sales |
| Revenue | ¥47.0bn | 2021-01-01 → 2021-12-31 | Standalone | Net sales |
| Revenue | ¥41.7bn | 2020-01-01 → 2020-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥43.0bn | 2019-01-01 → 2019-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥62.6bn | 2018-01-01 → 2018-12-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥5.5bn | 2022-01-01 → 2022-12-31 | Standalone | Operating income |
| Operating income | ¥4.7bn | 2021-01-01 → 2021-12-31 | Standalone | Operating income |
| Ordinary income | ¥5.5bn | 2022-01-01 → 2022-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥4.8bn | 2021-01-01 → 2021-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥5.0bn | 2020-01-01 → 2020-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.7bn | 2019-01-01 → 2019-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥5.1bn | 2018-01-01 → 2018-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥5.7bn | 2022-01-01 → 2022-12-31 | Standalone | Income before income taxes |
| Profit before tax | ¥4.8bn | 2021-01-01 → 2021-12-31 | Standalone | Income before income taxes |
| Net income | ¥3.9bn | 2022-01-01 → 2022-12-31 | Standalone | Profit loss |
| Net income | ¥3.4bn | 2021-01-01 → 2021-12-31 | Standalone | Profit loss |
| Net income | ¥3.5bn | 2020-01-01 → 2020-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥27.4bn | 2019-01-01 → 2019-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.2bn | 2018-01-01 → 2018-12-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥133.7bn | at 2022-12-31 | Standalone | Assets |
| Total assets | ¥130.8bn | at 2021-12-31 | Standalone | Assets |
| Total assets | ¥126.0bn | at 2020-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥139.9bn | at 2019-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥103.3bn | at 2018-12-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥14.5bn | at 2022-12-31 | Standalone | Liabilities |
| Total liabilities | ¥13.8bn | at 2021-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥119.2bn | at 2022-12-31 | Standalone | Net assets |
| Net assets / equity | ¥117.0bn | at 2021-12-31 | Standalone | Net assets |
| Net assets / equity | ¥115.1bn | at 2020-12-31d | Standalone | Net assets |
| Net assets / equity | ¥113.1bn | at 2019-12-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥87.1bn | at 2018-12-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥9.2bn | at 2022-12-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥4.0bn | at 2021-12-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥45.4bn | at 2022-12-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥58.4bn | at 2021-12-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥61.6bn | at 2020-12-31d | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥58.8bn | at 2019-12-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥15.7bn | at 2018-12-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥2.4bn | 2022-01-01 → 2022-12-31 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥156m | 2021-01-01 → 2021-12-31 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥3.4bn | 2020-01-01 → 2020-12-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥42.5bn | 2019-01-01 → 2019-12-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥8.3bn | 2018-01-01 → 2018-12-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥13.7bn | 2022-01-01 → 2022-12-31 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.5bn | 2021-01-01 → 2021-12-31 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | ¥7.6bn | 2020-01-01 → 2020-12-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥2.1bn | 2019-01-01 → 2019-12-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥27.1bn | 2018-01-01 → 2018-12-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥1.7bn | 2022-01-01 → 2022-12-31 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.5bn | 2021-01-01 → 2021-12-31 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.4bn | 2020-01-01 → 2020-12-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.4bn | 2019-01-01 → 2019-12-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.4bn | 2018-01-01 → 2018-12-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥140.39 | 2022-01-01 → 2022-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥120.13 | 2021-01-01 → 2021-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥124.47 | 2020-01-01 → 2020-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥974.98 | 2019-01-01 → 2019-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥41.51 | 2018-01-01 → 2018-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥124.46 | 2020-01-01 → 2020-12-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥100 | 2022-01-01 → 2022-12-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥48 | 2021-01-01 → 2021-12-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥48 | 2020-01-01 → 2020-12-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥48 | 2019-01-01 → 2019-12-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥48 | 2018-01-01 → 2018-12-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥4,243.08 | at 2022-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥4,165.38 | at 2021-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥4,097.55 | at 2020-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥4,029.3 | at 2019-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,103.28 | at 2018-12-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 89.2% | at 2022-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.5% | at 2021-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 91.3% | at 2020-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 80.8% | at 2019-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.3% | at 2018-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 3.3% | 2022-01-01 → 2022-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.9% | 2021-01-01 → 2021-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.1% | 2020-01-01 → 2020-12-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 27.3% | 2019-01-01 → 2019-12-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.3% | 2018-01-01 → 2018-12-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 28,800,000 | at 2022-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 28,800,000 | at 2021-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 28,800,000 | at 2020-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 28,800,000 | at 2019-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 28,800,000 | at 2018-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 563 | at 2022-12-31 | Standalone | Number of employees |
| Employees | 560 | at 2021-12-31 | Standalone | Number of employees |
| Employees | 568 | at 2020-12-31d | Standalone | Number of employees |
| Employees | 660 | at 2019-12-31d | Standalone | Number of employees |
| Employees | 1,049 | at 2018-12-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 1
| Segment | Item | Period | Value |
|---|---|---|---|
| Pharmaceutical Businessreportable segment | employees | at 2022-12-31 | 563 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 987
| Item | Context | Value | Unit |
|---|---|---|---|
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)㈱メディパルホールディングス | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)医薬品の販売等における円滑な取引関係を維持するために取得後、継続保有（注）３ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row2Member | Original text (Japanese)㈱スズケン | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row2Member | Original text (Japanese)医薬品の販売等における円滑な取引関係を維持するために取得後、継続保有（注）３ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row2Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row3Member | Original text (Japanese)アルフレッサ ホールディングス㈱ | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row3Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row3Member | Original text (Japanese)無（注）４ | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row4Member | Original text (Japanese)㈱バイタルケーエスケー・ホールディングス（注）２ | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row4Member | Original text (Japanese)医薬品の販売等における円滑な取引関係を維持するために取得後、継続保有（注）３ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row4Member | Original text (Japanese)無（注）４ | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row5Member | Original text (Japanese)東邦ホールディングス㈱（注）２ | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row5Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row5Member | Original text (Japanese)前事業年度：有当事業年度：無 （注）４ | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row6Member | Original text (Japanese)㈱ほくやく・竹山ホールディングス（注）２ | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row6Member | Original text (Japanese)医薬品の販売等における円滑な取引関係を維持するために取得後、継続保有（注）３ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row6Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row7Member | Original text (Japanese)㈱三井住友フィナンシャルグループ（注）２ | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row7Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row7Member | Original text (Japanese)無（注）４ | |
| Regulations in accordance with which financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYearDuration | Text · Plus | |
| Description of fact that consolidated financial statements have not been prepared financial information | CurrentYearDuration | Original text (Japanese)当社は子会社がありませんので、連結財務諸表を作成しておりません。 | |
| Remarkable efforts to ensure fair presentation of consolidated financial statements etc financial information | CurrentYearDuration | Text · Plus | |
| Balance sheet (text) | CurrentYearDuration | Text · Plus | |
| Statement of income (text) | CurrentYearDuration | Text · Plus | |
| Detailed schedule of manufacturing cost (text) | CurrentYearDuration | Text · Plus | |
| Detailed schedule of other cost (text) | CurrentYearDuration | Text · Plus | |
| Statement of changes in equity (text) | CurrentYearDuration | Text · Plus | |
| Statement of cash flows (text) | CurrentYearDuration | Text · Plus | |
| Notes significant accounting policies financial statements (text) | CurrentYearDuration | Text · Plus | |
| Significant accounting estimates financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes changes in accounting policies in accordance with changes in accounting standards etc financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes new accounting standards not yet applied financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding cash management system deposit (text) | CurrentYearInstant_NonConsolidatedMember | Text · Plus | |
| Notes regarding assets and liabilities incurred from transactions with affiliated entities (text) | CurrentYearInstant_NonConsolidatedMember | Text · Plus | |
| Notes regarding amount of revenue from contracts with customers (text) | CurrentYearDuration_NonConsolidatedMember | Text · Plus | |
| Notes regarding transactions with affiliated entities (text) | CurrentYearDuration_NonConsolidatedMember | Text · Plus | |
| Notes regarding transfer to other account (text) | CurrentYearDuration_NonConsolidatedMember | Text · Plus | |
| Notes regarding write downs of inventories (text) | CurrentYearDuration_NonConsolidatedMember | Text · Plus | |
| Research and development expenses included in general and administrative expenses and manufacturing cost for current period (text) | CurrentYearDuration_NonConsolidatedMember | Text · Plus | |
| Notes regarding loss on disposal of property plant and equipment (text) | CurrentYearDuration_NonConsolidatedMember | Text · Plus | |
| Restructuring expenses (text) | CurrentYearDuration_NonConsolidatedMember | Text · Plus | |
| Notes regarding issued shares and treasury shares (text) | Prior1YearDuration_NonConsolidatedMember | Text · Plus | |
| Notes regarding new share subscription rights etc (text) | Prior1YearDuration_NonConsolidatedMember | Text · Plus | |
| Notes regarding dividend (text) | Prior1YearDuration_NonConsolidatedMember | Text · Plus | |
| Notes regarding issued shares and treasury shares (text) | CurrentYearDuration_NonConsolidatedMember | Text · Plus | |
| Notes regarding new share subscription rights etc (text) | CurrentYearDuration_NonConsolidatedMember | Text · Plus | |
| Notes regarding dividend (text) | CurrentYearDuration_NonConsolidatedMember | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 13 of 13 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |